{
  "id": "5e2903978b3851296d000007",
  "type": "summary",
  "question": "Describe the mechanism of action of Luspatercept.",
  "ideal_answer": "Luspatercept is a recombinant soluble activin type-II receptor-IgG-Fc fusion protein that blocks transforming growth factor beta (TGF b) superfamily inhibitors of erythropoiesis. Luspatercept is tested for the treatment of various types of anemias.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30299326",
    "http://www.ncbi.nlm.nih.gov/pubmed/30285318",
    "http://www.ncbi.nlm.nih.gov/pubmed/28929587",
    "http://www.ncbi.nlm.nih.gov/pubmed/28870615",
    "http://www.ncbi.nlm.nih.gov/pubmed/30504333",
    "http://www.ncbi.nlm.nih.gov/pubmed/29499588",
    "http://www.ncbi.nlm.nih.gov/pubmed/30091846",
    "http://www.ncbi.nlm.nih.gov/pubmed/29193906",
    "http://www.ncbi.nlm.nih.gov/pubmed/29847322"
  ],
  "snippets": [
    {
      "text": "The method is a modification of a recently published protocol for Luspatercept (ACE-536, ACVR2B-Fc), another erythropoiesis stimulating fusion protein.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29193906",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "They are dimeric recombinant fusion proteins composed of the extracellular domain of a human activin receptor (ActRIIA or IIB) linked to the Fc part of human IgG1. Sotatercept (ActRIIA-Fc) and Luspatercept (a modified ActRIIB-Fc) in particular are now in phase 2/3 of clinical trials against anemia and included in the prohibited list established by the World Anti-Doping Agency. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29499588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE OF REVIEW: Sotatercept and luspatercept are recombinant soluble activin type-II receptor-IgG-Fc fusion proteins that are tested in clinical trials for the treatment of various types of anemias, including renal anemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29847322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Other newly developed ESAs - luspatercept and sotatercept, both activin receptor type II-Fc fusion proteins (ActRII-Fc) - are also now prohibited and could be used in combination with rEPOs. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30091846",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, activin inhibitors such as Luspatercept have shown to be effective in patients' refractory to ESAs and further clinical trials are ongoing to explore this further.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30299326",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Combined detection of the ActRII-Fc fusion proteins Sotatercept (ActRIIA-Fc) and Luspatercept (modified ActRIIB-Fc) in serum by means of immunoaffinity purification, tryptic digestion, and LC-MS/MS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30285318",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In particular, activin receptor competitors, such as the ActRII-Fc fusion proteins Sotatercept (ActRIIA-Fc) and Luspatercept (modified ActRIIB-Fc), have the potential for being misused as doping agents in sports as they were found to inhibit negative regulators of late-stage erythropoiesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30285318",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An example is luspatercept, an activin-receptor trap that modifies transforming growth factor-\u03b2 signaling, thereby increasing the efficiency of erythropoiesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30504333",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Myelodysplastic syndromes are characterised by ineffective erythropoiesis. Luspatercept (ACE-536) is a novel fusion protein that blocks transforming growth factor beta (TGF \u03b2) superfamily inhibitors of erythropoiesis, giving rise to a promising new investigative therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28870615",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Luspatercept (ACE-536) is a novel fusion protein that blocks transforming growth factor beta (TGF \u03b2) superfamily inhibitors of erythropoiesis, giving rise to a promising new investigative therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28870615",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Luspatercept (ACE-536, ACVR2B-Fc), a fusion protein consisting of the extracellular domain of ActRIIB receptor and the Fc-part of human immunoglobulin G1 (IgG1), is currently under clinical development (Phase III).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28929587",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotatercept and luspatercept are recombinant soluble activin type-II receptor-IgG-Fc fusion proteins that are tested in clinical trials for the treatment of various types of anemias , including renal anemia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29847322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Luspatercept (ACE-536) is a novel fusion protein that blocks transforming growth factor beta (TGF \u03b2) superfamily inhibitors of erythropoiesis, giving rise to a promising new investigative therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28870615",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several antibody-based strategies for the detection of Luspatercept and other ACVR2B-Fc fusion proteins in human serum were evaluated (ELISA; IEF-, SDS-, and SAR-PAGE followed by Western blotting; immunoprecipitation).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28929587",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Luspatercept (ACE-536, ACVR2B-Fc), a fusion protein consisting of the extracellular domain of ActRIIB receptor and the Fc-part of human immunoglobulin G1 (IgG1), is currently under clinical development (Phase III).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28929587",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE OF REVIEW\nSotatercept and luspatercept are recombinant soluble activin type-II receptor-IgG-Fc fusion proteins that are tested in clinical trials for the treatment of various types of anemias, including renal anemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29847322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several antibody-based strategies for the detection of Luspatercept and other ACVR2B-Fc fusion proteins in human serum were evaluated (ELISA; IEF-, SDS-, and SAR-PAGE followed by Western blotting; immunoprecipitation).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28929587",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}